The Latest Cardiac and Vascular News
European Approval Granted to Bayer Marks Another Important Milestone for VERQUVO KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for soluble guanylate cyclase (sGC) stimulator VERQUVO® (vericiguat). In […]
Innovative partnership focuses on early-stage development of activators for a glucose detoxification enzyme called glycerol-3-phosphate phosphatase (G3PP) MONTREAL, July 20, 2021 /PRNewswire/ — NIMIUM Therapeutics (www.nimium.ca), a Montreal-based biotech, has formed a partnership with Paraza Pharma (www.parazapharma.com) to develop a new treatment for cardiometabolic diseases (CMDs). The treatment aims to prevent and reverse the adverse […]
The implant, performed at the Azienda Ospedaliera dei Colli hospital in Naples, Italy, represents the first sale for CARMATand paves the way for the Company’s commercial development PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a […]
Abelacimab achieved a ~80% reduction in venous thromboembolism versus a standard of care comparator in gold standard proof-of-concept efficacy study, indicating its potential in a range of thromboembolic disorders CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final […]
Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy No Treatment Interruptions or Discontinuations Due to Reduction in Left Ventricular Ejection Fraction Phase 3 Registrational Trial of CK-274 Expected to Start Before […]
BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart disease and specific inborn errors of metabolism, today announced that the Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the […]
MANTRA is the new CORCYM post-market clinical follow-up study in a real-world setting LONDON–(BUSINESS WIRE)–CORCYM, the new, independent, medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the enrollment of the first patient in the MANTRA study. MANTRA (Mitral, Aortic […]
Elucid Founder, Andrew Buckler, To Present Findings at the SCCT Annual Scientific Meeting BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its founder Andrew Buckler will present findings from two separate studies […]
The implant was performed at Duke University Hospital, one of the largest U.S. cardiology centers PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage […]
SAN FRANCISCO & PARIS–(BUSINESS WIRE)–Viz.ai, the world leader in AI-driven intelligent care coordination, has partnered with Avicenna.AI, a global leader in artificial intelligence solutions, to enable intelligent care coordination and improve patient triage of patients suffering from pulmonary embolism (PE) and aortic disease. The collaboration will pave the way for faster […]
